Jump to content

Methyprylon: Difference between revisions

From Wikipedia, the free encyclopedia
Browse history interactively
← Previous editNext edit →
Content deleted Content added
VisualWikitext
CheMoBot (talk | contribs)
Bots
141,565 edits
Updating {{drugbox}} (changes to verified fields - updated 'ChEBI_Ref') per Chem/Drugbox validation (report errors or bugs)
Mr0t1633 (talk | contribs)
915 edits
Line 74: Line 74:
A study of single oral doses of 300&nbsp;mg in healthy volunteers found that the zero-order absorption model fit the data best. Mean (+/- SD) values for the half-life (9.2 +/- 2.2 h), apparent clearance, (11.91 +/- 4.42 mL/h/kg) and apparent steady-state volume of distribution, (0.97 +/- 0.33 L/kg) were found.<ref>{{ cite pmid | 2866242 }}</ref>
A study of single oral doses of 300&nbsp;mg in healthy volunteers found that the zero-order absorption model fit the data best. Mean (+/- SD) values for the half-life (9.2 +/- 2.2 h), apparent clearance, (11.91 +/- 4.42 mL/h/kg) and apparent steady-state volume of distribution, (0.97 +/- 0.33 L/kg) were found.<ref>{{ cite pmid | 2866242 }}</ref>


A case report found the pharmacokinetics of methyprylon nonlinear (concentration dependent) in an overdose case; explanations included saturation or inhibition of metabolic pathways. The generally accepted half-life for a therapeutic dose was not found appropriate in intoxicated patients and would underestimate the time required to reach a safe concentration of the drug.<ref>{{ cite pmid | 1686463 }}</ref>
A case report found that the pharmacokinetics of methyprylon were not concentration dependent in an overdose case; explanations included saturation or inhibition of metabolic pathways. The generally accepted half-life for a therapeutic dose was not found appropriate in intoxicated patients and would underestimate the time required to reach a safe concentration of the drug.<ref>{{ cite pmid | 1686463 }}</ref>


== Synthesis ==
== Synthesis ==

Revision as of 01:34, 8 October 2012

Methyprylon
Clinical data
Trade namesDimerin, Methyprylone, Noctan, Noludar
Routes of
administration		oral
ATC code
Legal status
Legal status
Pharmacokinetic data
Protein binding60%
Elimination half-life6-16 hours
Identifiers
  • (RS)-3,3-diethyl-5-methylpiperidine-2,4-dione
CAS Number
PubChem CID
DrugBank
ChemSpider
UNII
KEGG
ChEMBL
CompTox Dashboard (EPA)
ECHA InfoCard100.004.315 Edit this at Wikidata
Chemical and physical data
FormulaC10H17NO2
Molar mass183.248 g/mol g·mol−1
  • InChI=1S/C10H17NO2/c1-4-10(5-2)8(12)7(3)6-11-9(10)13/h7H,4-6H2,1-3H3,(H,11,13) checkY
  • Key:SIDLZWOQUZRBRU-UHFFFAOYSA-N checkY
 ☒NcheckY (what is this?)  (verify)

Methyprylon (Noludar) is a sedative of the piperidinedione derivative family developed by Hoffmann-La Roche.[1] This medicine was used for treating insomnia, but is now rarely used as it has been replaced by newer drugs with fewer side effects, such as benzodiazepines.[2] Methyprylon was withdrawn from the US market in June 1989 and the Canadian market in September 1990.

Adverse effects

Side effects can include: Skin rash, fever, depression, ulcers or sores in mouth or throat, unusual bleeding or bruising, confusion, fast heartbeat, respiratory depression, swelling of feet or lower legs, dizziness, drowsiness, headache, double vision, clumsiness, constipation, diarrhea, nausea, vomiting, unusual weakness.[citation needed]

Pharmacokinetics

A study of single oral doses of 300 mg in healthy volunteers found that the zero-order absorption model fit the data best. Mean (+/- SD) values for the half-life (9.2 +/- 2.2 h), apparent clearance, (11.91 +/- 4.42 mL/h/kg) and apparent steady-state volume of distribution, (0.97 +/- 0.33 L/kg) were found.[3]

A case report found that the pharmacokinetics of methyprylon were not concentration dependent in an overdose case; explanations included saturation or inhibition of metabolic pathways. The generally accepted half-life for a therapeutic dose was not found appropriate in intoxicated patients and would underestimate the time required to reach a safe concentration of the drug.[4]

Synthesis

Methyprylon may be synthesized starting from an aldol condensation of ethyl 2,2-diethyl-3-oxobutanoate with ethyl formate. The resulting enol is converted to the lactam pyrithyldione by treating with ammonia and heating. The lactam is formylated at postion-5 and reduced to yield methyprylon.[5]

See also

References

  1. ^ US patent 2680116, Frick, H. & Lutz, A. H., "Piperidiones and Process for the Manufacture thereof", issued 1954-06-01, assigned to Hoffmann-La Roche 
  2. ^ Attention: This template ({{cite pmid}}) is deprecated. To cite the publication identified by PMID 16792 , please use {{cite journal}} with |pmid= 16792 instead.
  3. ^ Attention: This template ({{cite pmid}}) is deprecated. To cite the publication identified by PMID 2866242 , please use {{cite journal}} with |pmid= 2866242 instead.
  4. ^ Attention: This template ({{cite pmid}}) is deprecated. To cite the publication identified by PMID 1686463 , please use {{cite journal}} with |pmid= 1686463 instead.
  5. ^ Attention: This template ({{cite pmid}}) is deprecated. To cite the publication identified by PMID 13161893 , please use {{cite journal}} with |pmid= 13161893 instead.


Stub icon

This medical article is a stub. You can help Wikipedia by expanding it.

Retrieved from "https://en.wikipedia.org/enwiki/w/index.php?title=Methyprylon&oldid=516561606"